Rekombinanter PDCD1 (Nivolumab Biosimilar) Antikörper

Produktnummer ABIN7200667

Produktdetails anti-PDCD1 (Nivolumab Biosimilar) Antikörper

Target: PDCD1 (Nivolumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PDCD1 (Nivolumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Verwendungszweck: Nivolumab Biosimilar, Human PD-1 Monoclonal Antibody

Spezifität: The in vivo grade nivolumab biosimilar specifically binds to PD-1, antagonizing its interaction with its known ligands PD-L1 and PD-L2.

Produktmerkmale: Recombinant Humanized IgG4 Monoclonal Antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody nivolumab biosimilar was produced in the nivolumab biosimilar CHO stable cell line.

Klon: 5C4-B8

Isotyp: IgG4 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nivolumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu PDCD1 (Nivolumab Biosimilar)

Target: PDCD1 (Nivolumab Biosimilar)

Abstract: PDCD1 (Nivolumab Biosimilar) Produkte

Substanzklasse: Biosimilar

Hintergrund: What is Nivolumab biosimilar research grade? Nivolumab is a humanized IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. Nivolumab Biosimilar uses the same protein sequences as the therapeutic antibody nivolumab.

PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1).

Nivolumab blocks PD-1 inhibitory signalling to T-cells. It has a long duration of action as it is administered every 2-4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion-related adverse effects, complications of allogenic hematopoietic stem cell transplants, embryo-fetal toxicity.

The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response.